We are leading experts in lysosomal storage disorders.
Below please find a few of the most recent scientific publications developed by members of the M6P clinical development team:
Mucolipidosis type II AAV9 gene therapy pilot study (M002): In vivo safety of over-expressing modified GlcNAc-1-phosphotransferase (S1S3) in wild-type mice. Poster session at WORLDSymposium, Feb. 12, 2021.
Phosphorylated acid β-glucosidase (M011, GCaseM6P) enzyme replacement therapy leads to better tissue distribution, cellular uptake, and efficacy in the Gaucher D409A mouse model compared to conventional α-mannosyl terminated β-glucosidase. Poster session at WORLDSymposium, Feb. 12, 2021.
A new platform technology for next generation lysosomal enzyme replacement and potential gene therapy in the treatment of lysosomal diseases. Poster session at WORLDSymposium, Feb. 11, 2020.
Engineering Of GlcNAc-1-Phosphotransferase For Production Of Highly Phosphorylated Lysosomal Enzymes For Enzyme Replacement Therapy. Mol Ther Methods Clin Dev. 2017 Jun 16; 5: 59–65.